3 (Dose climbing):CAR-T cell therapy
Sponsors
the First Affiliated Hospital, Zhejiang University School of Medicine
Conditions
Relapsed and refractory acute B lymphocytic leukemiaautoimmune diseases
Phase 1
A clinical study on the safety and effectiveness of CD19/BCMA chimeric antigen receptor T cells in the treatment of auto-antibody-mediated autoimmune diseases and HLA antibody-positive status before allogeneic hematopoietic stem cell transplantation
RecruitingChiCTR2100049920
Start: 2020-03-01Updated: 2022-04-19
A clinical study on the safety and effectiveness of CD19 CAR-T and CD22 CAR-T sequential treatment of relapsed and refractory acute B lymphocytic leukemia
RecruitingChiCTR2100052009
Start: 2020-11-21Updated: 2022-06-27